I
Ian D. Pavord
Researcher at University of Oxford
Publications - 654
Citations - 55329
Ian D. Pavord is an academic researcher from University of Oxford. The author has contributed to research in topics: Asthma & Sputum. The author has an hindex of 108, co-authored 575 publications receiving 47691 citations. Previous affiliations of Ian D. Pavord include John Radcliffe Hospital & University of Warwick.
Papers
More filters
Journal ArticleDOI
Measurement of exhaled nitric oxide fails to predict left atrial pressure assessed by E/e ratio in elderly patients.
Samuel Thomas Jones,Monica Londahl,Anthony Prothero,Richard J. Hobbs,Ian D. Pavord,Saul G. Myerson,Bernard Prendergast,Sean Coffey +7 more
TL;DR: In this article , the authors examined the strength of association between fractional exhaled nitric oxide (FeNO) and echocardiographic assessment of LAP by the E/e' ratio to determine if FeNO could be used to identify those with elevated LAP.
Journal ArticleDOI
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose.
Ian D. Pavord,Arnaud Bourdin,Alberto Papi,Christian Domingo,Jonathan Corren,Arman Altincatal,Amr Radwan,Nami Pandit-Abid,Juby A. Jacob-Nara,Yamo Deniz,Paul Rowe,Elizabeth Laws,David J. Lederer,Megan Hardin +13 more
TL;DR: In this paper , dupilumab showed sustained efficacy for up to 3 years in patients with uncontrolled, moderate-to-severe type 2 asthma on high- or medium-dose ICS.
Journal ArticleDOI
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases.
Praveen Akuthota,Rebeca Andradas,Amanda Cordell,Sarah Gray,Joyce Kullman,Sameer K. Mathur,Ian D. Pavord,Florence Roufosse,Christian Rubio,Irena Clisson Rusek,Dagmar Simon,Mary Jo Strobel,Tonya Winders +12 more
TL;DR: In this paper , the authors present a patient charter to describe the key elements of good quality care for people with EADs and present an action plan to improve health and overall well-being.
Journal ArticleDOI
Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals With Refractory Or Unexplained Chronic Cough Enrolled In Phase 3 Trials Of Gefapixant
Michael S. Blaiss,Peter V. Dicpinigaitis,Surinder S. Birring,Lorcan McGarvey,Alyn H. Morice,Ian D. Pavord,Imran Satia,Jaclyn A. Smith,Carmen La Rosa,Qing Li,Allison Martin Nguyen,J. Schelfhout,A. Tzontcheva,David Muccino +13 more
TL;DR: In this article , pooled data from two gefapixant phase 3 trials evaluated subgroups of patients with RCC vs UCC and found that RCC was nonsuggestive of contributory comorbidities despite clinical evaluation.
Journal ArticleDOI
Case-finding and diagnosis of obstructive airway diseases: the Dragons’ Den experience
TL;DR: In this paper , a 10-year life sciences mission in respiratory medicine to focus on preventing, diagnosing, monitoring, and treating common diseases early is proposed, with the goal to reduce mortality and morbidity from respiratory disease in the UK and globally.